Purple Biotech Ltd. (PPBT) stock
PPBTNasdaqPharmaceutical PreparationsFiscal year ends December 31
$1.63+0.07 (+4.49%)
Close on Nov 13, 2026Market cap $1.52MP/E 0.0Yield –
Earnings
Purple Biotech's quarterly results as reported in its earnings releases, with the company's own outlook. Hover a number to see the sentence it came from.
Next report
–
Not yet scheduled
Revenue, Q4 FY2025
–
EPS, Q4 FY2025
$0.10
Latest guidance
None
No outlook given in releases
Quarterly results
Revenue and earnings per share from each of Purple Biotech's earnings releases, newest first
| Quarter | Reported | Revenue | YoY | EPS | Source |
|---|---|---|---|---|---|
| Q4 FY2025ended Dec 31, 2025 | Mar 13, 2026before the open | – | – | $0.10 | Release |
| Q4 FY2024ended Dec 31, 2024 | Mar 10, 2025before the open | – | – | – | Release |
| Q4 FY2023ended Dec 31, 2023 | Mar 5, 2024before the open | – | – | $0.19 | Release |
| Q4 FY2022ended Dec 31, 2022 | Feb 8, 2023before the open | – | – | – | Release |
| Q4 FY2021ended Dec 31, 2021 | Feb 9, 2022before the open | – | – | – | Release |
Figures as first announced; later restatements appear under Financials. Expected dates are estimated from the company's past reporting pattern.
Guidance
Purple Biotech has not given guidance in its releases
Many companies give their outlook only on the conference call or not at all. When Purple Biotech puts a forecast in an earnings release, it is listed here with the exact sentence.
Press releases
Releases Purple Biotech filed with the SEC as exhibits to Form 8-K or 6-K
- 6-K
- 6-K
- 6-K
- 6-K
- 6-K
- 6-K
- 6-K
- 6-K
- 6-K
- 6-K
- 6-K
- 6-K
- 6-K
- 6-K
- 6-K
See a number that looks wrong?